Eric Adler - 02 Feb 2024 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role: Chief Medical Officer
Signature: /s/ Jenny Robertson, attorney-in-fact
Issuer symbol: LXEO
Transactions as of: 02 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 06 Feb 2024, 17:56:14 UTC
Previous filing: 02 Nov 2023
Next filing: 10 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LXEO	Common Stock	Award	$0	+26,875		$0.000000	26,875	02 Feb 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LXEO	Employee Stock Option (right to buy)	Award	$0	+161,250		$0.000000	161,250	02 Feb 2024	Common Stock	161,250	$17.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2025, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
F2	25% of the shares underlying the option vest and become exercisable on February 2, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Content

The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2025, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.

25% of the shares underlying the option vest and become exercisable on February 2, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.